DelveInsight has launched a new report on “Familial Hypercholesterolemia (FH) – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Familial Hypercholesterolemia (FH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
A review indicates that Heterozygous FH is much more frequent in comparison with Homozygous FH. As per the estimates provided by this review, the reported prevalence of FH is 1 in 200-1 in 500 for heterozygous state and 1 in 160,000-1 in 1,000, 000 for homozygous state, respectively.
-
As per a study the estimated overall US prevalence of probable/definite FH was 0.40% (95% confidence interval, 0.32–0.48) or 1 in 250 (95% confidence interval, 1 in 311 to 209). Furthermore, the study had also reported that FH prevalence in the US is varied by age, being least common in 20-29 years old and most common in 60-69 years old.
-
According to the estimates, the reported prevalence of heterozygous familial hypercholesterolemia in the UK population is estimated to be 1 in 500.
Key benefits of the report:
1. Familial Hypercholesterolemia (FH) market report covers a descriptive overview and comprehensive insight of the Familial Hypercholesterolemia (FH) epidemiology and Familial Hypercholesterolemia (FH) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Familial Hypercholesterolemia (FH) market report provides insights on the current and emerging therapies.
3. Familial Hypercholesterolemia (FH) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Familial Hypercholesterolemia (FH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia (FH) market.
Request for sample pages: https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report
Familial Hypercholesterolemia (FH): Overview
Familial hypercholesterolemia (FH) is a common life-threatening genetic condition that causes high cholesterol. Untreated, FH leads to early heart attacks and heart disease.People with FH have a high amount of low density lipoprotein (LDL) or “bad cholesterol” due to a mutation in one of the genes that controls the way cholesterol is cleared by the body. As a result, cholesterol accumulates in the bloodstream and can ultimately build up in the walls of the arteries. Cholesterol build up in the artery wall is called hardening of the arteries, or atherosclerosis, and can lead to problems such as heart attacks and strokes in young adults and even children.
The key players involved in Familial Hypercholesterolemia (FH) market:
-
Genzyme
-
Amryt Pharmaceuticals
-
AstraZeneca
The launch of the emerging therapies is expected to significantly impact the Familial Hypercholesterolemia (FH) treatment scenario in the upcoming years:-
Drug covered
-
KYNAMRO
-
Lojuxta
-
CRESTOR
Request a free sample report @https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Familial Hypercholesterolemia (FH) Patient Share (%) Overview at a Glance
5. Familial Hypercholesterolemia (FH) Market Overview at a Glance
6. Familial Hypercholesterolemia (FH) Disease Background and Overview
7. Familial Hypercholesterolemia (FH) Epidemiology and Patient Population
8. Country-Specific Patient Population of Familial Hypercholesterolemia (FH)
9. Familial Hypercholesterolemia (FH) Current Treatment and Medical Practices
10. Unmet Needs
11. Familial Hypercholesterolemia (FH) Emerging Therapies
12. Familial Hypercholesterolemia (FH) Market Outlook
13. Country-Wise Familial Hypercholesterolemia (FH) Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Familial Hypercholesterolemia (FH) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Familial Hypercholesterolemia (FH) – Epidemiology Forecast to 2030
DelveInsight’s ‘Familial Hypercholesterolemia (FH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia (FH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/